Limits...
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.

Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A - Emerging Infect. Dis. (2015)

Bottom Line: Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F.Our data do not support or exclude cross-protection against serotype 19A.

View Article: PubMed Central - PubMed

ABSTRACT
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F. Our data do not support or exclude cross-protection against serotype 19A.

No MeSH data available.


Related in: MedlinePlus

Age-specific incidence of invasive pneumococcal disease caused by any serotype of Streptococcus pneumoniae per epidemiologic year (June–May), the Netherlands. Vertical dashed lines indicate introduction of 7-valent pneumococcal conjugate vaccine in June 2006 and 10-valent pneumococcal conjugate vaccine in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4622227&req=5

Figure 1: Age-specific incidence of invasive pneumococcal disease caused by any serotype of Streptococcus pneumoniae per epidemiologic year (June–May), the Netherlands. Vertical dashed lines indicate introduction of 7-valent pneumococcal conjugate vaccine in June 2006 and 10-valent pneumococcal conjugate vaccine in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.

Mentions: A total of 6,292 IPD cases were included in sentinel surveillance during June 2004–May 2014. By 2009–2011, overall IPD incidence had decreased by 57% for children <2 years of age, 47% for children 2–4 years of age, and 22% for persons >65 years of age (Figure 1; Table 1). No further decrease was observed during 2011–2014 for persons >65 years of age. PCV7 IPD incidence decreased for all age groups, and the decrease continued and showed an overall reduction of 90% by 2013–2014 (Figure 2, panel A). Non-PCV7 IPD incidence increased by 38% for all age groups from 2004–2006 to 2009–2011 (Figure 2, panel B; Table 1).


Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.

Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A - Emerging Infect. Dis. (2015)

Age-specific incidence of invasive pneumococcal disease caused by any serotype of Streptococcus pneumoniae per epidemiologic year (June–May), the Netherlands. Vertical dashed lines indicate introduction of 7-valent pneumococcal conjugate vaccine in June 2006 and 10-valent pneumococcal conjugate vaccine in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4622227&req=5

Figure 1: Age-specific incidence of invasive pneumococcal disease caused by any serotype of Streptococcus pneumoniae per epidemiologic year (June–May), the Netherlands. Vertical dashed lines indicate introduction of 7-valent pneumococcal conjugate vaccine in June 2006 and 10-valent pneumococcal conjugate vaccine in May 2011. Incidences are based on sentinel surveillance data and extrapolated to the national level.
Mentions: A total of 6,292 IPD cases were included in sentinel surveillance during June 2004–May 2014. By 2009–2011, overall IPD incidence had decreased by 57% for children <2 years of age, 47% for children 2–4 years of age, and 22% for persons >65 years of age (Figure 1; Table 1). No further decrease was observed during 2011–2014 for persons >65 years of age. PCV7 IPD incidence decreased for all age groups, and the decrease continued and showed an overall reduction of 90% by 2013–2014 (Figure 2, panel A). Non-PCV7 IPD incidence increased by 38% for all age groups from 2004–2006 to 2009–2011 (Figure 2, panel B; Table 1).

Bottom Line: Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F.Our data do not support or exclude cross-protection against serotype 19A.

View Article: PubMed Central - PubMed

ABSTRACT
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F. Our data do not support or exclude cross-protection against serotype 19A.

No MeSH data available.


Related in: MedlinePlus